CK2.18
Casein Kinase 2 Inhibitor Peptide CK2.18
A cell-permeable peptide inhibitor of casein kinase 2 (CK2) that has demonstrated the ability to selectively eliminate senescent cells (senolytics) and extend lifespan in model organisms.
Mechanism of Action
CK2.18 inhibits CK2-mediated phosphorylation of p21 and other senescence-associated proteins, disrupting the pro-survival signaling that allows senescent cells to resist apoptosis. This selectively clears senescent cells while sparing healthy proliferating cells, reducing the senescence-associated secretory phenotype (SASP).
Health Claims & Evidence
Selectively clears senescent cells (senolytic activity)
Reduces SASP-driven chronic inflammation
Extends healthspan in model organisms
Short-Term Effects
Unknown in humans.
Long-Term Effects
Unknown in humans. Animal data suggests healthspan extension.
Side Effects
Unknown in humans.
Contraindications
Insufficient human data. Not for clinical use.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
CK2 inhibition and cellular senescence
Litovchick et al. · Science Signaling · 2011
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on CK2.18 and related peptides, and prepare an educational research summary.
Explore Research